WHO ICTRP trial
A clinical study to assess the efficacy and safety of Tedizolid Tablets for the…
CTRI/2023/12/060921 · Clinical Trials Registry India (CTRI) · Not Recruiting
Key facts
| Trial ID | CTRI/2023/12/060921 |
|---|---|
| Public title | A clinical study to assess the efficacy and safety of Tedizolid Tablets for the treatment of bacterial skin infections. |
| Scientific title | A Phase III, Prospective, Randomized, Double Blind, Double Dummy, Active Controlled, Comparative, Parallel Group, Multicenter Clinical Study to Evaluate the Efficacy, Safety and Tolerability of Tedizolid Tablets 200 mg Versus Linezolid Tablets 600 mg in Adult Patients for the Treatment of Acute… |
| Primary sponsor | Exemed Pharmaceuticals |
| Registry | Clinical Trials Registry India (CTRI) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | Phase 3 |
| Countries | India |
| Conditions | Health Condition 1: L039- Cellulitis and acute lymphangitis,unspecified |
| Interventions | Intervention1: Tedizolid Tablets 200 mg: Patients will be advised to take one Tablet of Tedizolid Tablets 200 mg plus one Tablet of Placebo followed 12 hours later by one Tablet of Placebo from day 1 to day 6, and 3 Tablets of Placebo from… |
| Registration date | Dec 28, 2023 |
| Target size | 242 |
| Secondary IDs | CT/2023/25, Version No.: 00 and Dated Apr 20, 2023 |
| Registry page | ctri.nic.in |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: